Mopar, prior to the earnings report I was doing extensive research into the Teva candidate speculation. I was one of the advocates of Seroquel last year as well but I knew at that time Teva had (4) strengths already but none of them are extended release. I just went down the list of our oldest ANDA and stopped there as I didn't think we would reasonably get an approval of anything after Seroquel anytime soon. Prior to your post I have evidence that Pristiq was their choice all along but the evidence wasn't available when we were speculating 2-2-15.
For the record, even though the pr says they'll change their candidate, I still think Pristiq is on their radar.
News 
Market Data 
Discover 
AI
